Crataegus · hawthorn berry · mayblossom · whitethorn
600 mg · vegan · gluten-free · 90 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
Hawthorn (Crataegus species) is a thorny shrub whose leaves, berries, and flowers have been used in European traditional medicine for cardiovascular conditions for over 2,000 years. Modern extracts are standardized to flavonoid or procyanidin content.
Hawthorn increases coronary blood flow, improves myocardial contractility through PDE inhibition, reduces peripheral vascular resistance, and exhibits antioxidant properties in cardiac tissue. It also modulates angiotensin-converting enzyme activity.
Adults with mild-to-moderate chronic heart failure (NYHA I-II), individuals seeking cardiovascular support, those with reduced exercise tolerance, people interested in traditional European botanicals.
People with severe heart failure (NYHA III-IV), those taking digoxin or antiarrhythmics (potential interaction), pregnant or breastfeeding women, children, individuals with hypotension.
Pick a depth — minimum to maximal coverage
No full stack configured.
Click individual supplement pills above to buy each on Amazon India.
✓ Morning and evening for sustained cardiovascular support
✓ Food improves absorption and reduces GI discomfort
Hawthorn increases coronary blood flow, improves myocardial contractility through PDE inhibition, reduces peripheral vascular resistance, and exhibits antioxidant properties in cardiac tissue.
Each bar = one cited trial. Effect varies by methodology, dose, and population.
Representative cohort from published RCT data
Relative to baseline (100). Data from published clinical literature.
see study
→ Meta-analysis: hawthorn improved exercise tolerance and symptoms vs placebo; no mortality benefit (N=10 trials)
see study
→ WS 1442 900 mg/day showed trend toward reduced sudden cardiac death (N=2,681, 24 months)
see study
→ WS 1442 improved exercise tolerance by 28% and reduced fatigue vs placebo (N=209, 6 months)
B · Consistent improvement in exercise tolerance and symptoms; no proven mortality benefit; SPICE trial showed trend but not significance; well-established in European phytomedicine
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: PMID 18450322 (Pittler 2008, heart failure meta-analysis), PMID 23471642 (Tassell 2010, blood pressure review), PMID 22291378 (Rigelsky 2002, cardiac function review).
How to use Hawthorn specifically for shortness of breath — the right dose, timing, blood markers to track, and how to know if it is working.
A clinical evidence review of Hawthorn — RCT data, effect sizes, evidence grade, and what the numbers mean for your specific situation.
Everything you need to know about Hawthorn — mechanism, dose, safety, buying guide for India, and what the research actually says.
SacredBod's longer take on Hawthorn — context the structured blocks above don't capture.
Hawthorn is one of the most extensively studied botanicals for cardiovascular disease, with a research history spanning decades and a traditional use history spanning millennia. The German Commission E—the regulatory body for herbal medicines—officially approves hawthorn for NYHA Class I-II heart failure, a status that reflects both clinical evidence and regulatory confidence. The extract standardized as WS 1442 (Crataegus special extract) has been the subject of multiple large trials.
The symptomatic benefits are well-established. Pittler and colleagues (2008, Cochrane Database of Systematic Reviews, PMID 18425885) conducted a meta-analysis of 10 randomized trials including 855 patients with chronic heart failure. Hawthorn extract significantly improved maximal workload, exercise tolerance, and symptoms (dyspnea and fatigue) compared to placebo. The effect sizes were modest but consistent—patients could walk further and felt less exhausted. However, the Cochrane review explicitly noted that there was no significant effect on mortality or progression to severe heart failure. Hawthorn improves quality of life; it does not alter disease trajectory.
The SPICE trial (Holubarsch et al., 2008, European Journal of Heart Failure, PMID 18456557) was the largest and most ambitious hawthorn study. It randomized 2,681 patients with NYHA Class II-III heart failure to WS 1442 900 mg daily or placebo for 24 months. The primary endpoint—time to first cardiac event—was not significantly different between groups. However, a prespecified secondary analysis showed a trend toward reduced sudden cardiac death in the hawthorn group (HR 0.81, p=0.08). This near-significant finding generated interest but does not meet the threshold for clinical recommendation. The honest framing: hawthorn is safe and improves symptoms, but it has not been proven to prevent hospitalization or death.
The mechanistic basis is multifaceted. Hawthorn increases coronary blood flow through nitric oxide-mediated vasodilation, improves myocardial contractility through phosphodiesterase inhibition (similar to milrinone but much milder), and reduces afterload through peripheral vasodilation. These are real pharmacological effects, not placebo. The safety profile is excellent—side effects are rare and mild, primarily gastrointestinal. However, the interaction potential is real: hawthorn may potentiate digoxin, antiarrhythmics, and blood pressure medications. It should not be used in severe heart failure (NYHA III-IV) where pharmaceutical therapy is essential.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
